Learn more about D. Ross Camidge, MD, PhD, University of Colorado, Director of the Academic Thoracic Oncology Medical Investigators’ Consortium (ATOMIC), who was honored by a colleague for the 2023 Healio Honors in Medical Oncology.
Continue readingInterview with Dr. Matthew Milowsky of the Academic Urology Research Investigators Consortium (AURIC)
Dr. Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab.
Continue readingCU Cancer Center’s D. Ross Camidge, MD, PhD, Honored by the International Association for the Study of Lung Cancer(IASLC)
Dr. Camidge received the organization’s Daniel C. Ihde Lectureship Award for Medical Oncology.
Continue readingDr. D. Ross Camidge and Dr. Peter Kabos Win University of Colorado Recognition Awards
Dr. Peter Kabos, MD, Associate Professor, Division of Medical Oncology and Dr. D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology were recently honored by the University of Colorado’s Division of Medical Oncology.
Continue readingATOMIC Investigators Meeting – Investigators Meet at IASLC For the First Time Since Covid
ATOMIC (Academic Thoracic Oncology Medical Investigators Consortium), met at the IASLC 2023 Targeted Therapies of Lung Cancer symposium in February in Santa Monica.
Continue readingAGICC Investigator’s Meeting – Investigators Meet at ASCO GI For the First Time Since Covid
AGICC (Academic GI Cancer Consortium) met in person for an Investigator’s Meeting during the recent GI-ASCO 2023 Symposium in San Francisco. This coming year the AGICC group will continue to explore GI oncology trials in partnership with pharmaceutical companies.
Continue readingAURIC Investigator’s Meeting – Successful First Meeting of Newly Formed Group
The Academic Urology Research Investigators Consortium met for an initial Investigator’s Meeting during the recent GU-ASCO 2023 in San Francisco to explore new studies for the coming year. The group’s primary focus is to partner with pharmaceutical companies looking to explore novel genitourinary oncology trials.
Continue reading



